Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients

Abstract Background Cancer-therapy related cardiac dysfunction (CTRCD) remains a significant cause of morbidity and mortality in cancer survivors. In this study, we aimed to identify differential plasma proteins and metabolites associated with left ventricular dysfunction (LVD) in cancer patients. M...

Full description

Saved in:
Bibliographic Details
Main Authors: Jessica C. Lal, Michelle Z. Fang, Muzna Hussain, Abel Abraham, Reina Tonegawa-Kuji, Yuan Hou, Mina K. Chung, Patrick Collier, Feixiong Cheng
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Cardio-Oncology
Subjects:
Online Access:https://doi.org/10.1186/s40959-025-00309-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850067629112295424
author Jessica C. Lal
Michelle Z. Fang
Muzna Hussain
Abel Abraham
Reina Tonegawa-Kuji
Yuan Hou
Mina K. Chung
Patrick Collier
Feixiong Cheng
author_facet Jessica C. Lal
Michelle Z. Fang
Muzna Hussain
Abel Abraham
Reina Tonegawa-Kuji
Yuan Hou
Mina K. Chung
Patrick Collier
Feixiong Cheng
author_sort Jessica C. Lal
collection DOAJ
description Abstract Background Cancer-therapy related cardiac dysfunction (CTRCD) remains a significant cause of morbidity and mortality in cancer survivors. In this study, we aimed to identify differential plasma proteins and metabolites associated with left ventricular dysfunction (LVD) in cancer patients. Methods We analyzed data from 50 patients referred to the Cleveland Clinic Cardio-Oncology Center for echocardiograph assessment, integrating electronic health records, proteomic, and metabolomic profiles. LVD was defined as an ejection fraction ≤ 55% based on echocardiographic evaluation. Classification-based machine learning models were used to predict LVD using plasma metabolites and proteins as input features. Results We identified 13 plasma proteins (P < 0.05) and 14 plasma metabolites (P < 0.05) associated with LVD. Key proteins included markers of inflammation (ST2, TNFRSF14, OPN, and AXL) and chemotaxis (RARRES2, MMP-2, MEPE, and OPN). Notably, sex-specific associations were observed, such as uridine (P = 0.003) in males. Furthermore, metabolomic features significantly associated with LVD included 1-Methyl-4-imidazoleacetic acid (P = 0.015), COL1A1 (P = 0.009), and MMP-2 (P = 0.016), and pointing to metabolic shifts and heightened inflammation in patients with LVD. Conclusion Our findings suggest that circulating metabolites may non-invasively detect clinical and molecular differences in patients with LVD, providing insights into underlying disease pathways and potential therapeutic targets.
format Article
id doaj-art-4097e02a2d254cbfb52700306d6577dd
institution DOAJ
issn 2057-3804
language English
publishDate 2025-02-01
publisher BMC
record_format Article
series Cardio-Oncology
spelling doaj-art-4097e02a2d254cbfb52700306d6577dd2025-08-20T02:48:16ZengBMCCardio-Oncology2057-38042025-02-0111111210.1186/s40959-025-00309-6Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patientsJessica C. Lal0Michelle Z. Fang1Muzna Hussain2Abel Abraham3Reina Tonegawa-Kuji4Yuan Hou5Mina K. Chung6Patrick Collier7Feixiong Cheng8Genomic Medicine Institute, Lerner Research Institute, Cleveland ClinicGenomic Medicine Institute, Lerner Research Institute, Cleveland ClinicDepartment of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland ClinicDepartment of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland ClinicGenomic Medicine Institute, Lerner Research Institute, Cleveland ClinicGenomic Medicine Institute, Lerner Research Institute, Cleveland ClinicDepartment of Cardiovascular Medicine, Heart, Vascular & Thoracic Institute, Cleveland ClinicDepartment of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve UniversityGenomic Medicine Institute, Lerner Research Institute, Cleveland ClinicAbstract Background Cancer-therapy related cardiac dysfunction (CTRCD) remains a significant cause of morbidity and mortality in cancer survivors. In this study, we aimed to identify differential plasma proteins and metabolites associated with left ventricular dysfunction (LVD) in cancer patients. Methods We analyzed data from 50 patients referred to the Cleveland Clinic Cardio-Oncology Center for echocardiograph assessment, integrating electronic health records, proteomic, and metabolomic profiles. LVD was defined as an ejection fraction ≤ 55% based on echocardiographic evaluation. Classification-based machine learning models were used to predict LVD using plasma metabolites and proteins as input features. Results We identified 13 plasma proteins (P < 0.05) and 14 plasma metabolites (P < 0.05) associated with LVD. Key proteins included markers of inflammation (ST2, TNFRSF14, OPN, and AXL) and chemotaxis (RARRES2, MMP-2, MEPE, and OPN). Notably, sex-specific associations were observed, such as uridine (P = 0.003) in males. Furthermore, metabolomic features significantly associated with LVD included 1-Methyl-4-imidazoleacetic acid (P = 0.015), COL1A1 (P = 0.009), and MMP-2 (P = 0.016), and pointing to metabolic shifts and heightened inflammation in patients with LVD. Conclusion Our findings suggest that circulating metabolites may non-invasively detect clinical and molecular differences in patients with LVD, providing insights into underlying disease pathways and potential therapeutic targets.https://doi.org/10.1186/s40959-025-00309-6CardiotoxicityMachine learning modelsMulti-omicsPlasma proteomicsPlasma metabolomics
spellingShingle Jessica C. Lal
Michelle Z. Fang
Muzna Hussain
Abel Abraham
Reina Tonegawa-Kuji
Yuan Hou
Mina K. Chung
Patrick Collier
Feixiong Cheng
Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients
Cardio-Oncology
Cardiotoxicity
Machine learning models
Multi-omics
Plasma proteomics
Plasma metabolomics
title Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients
title_full Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients
title_fullStr Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients
title_full_unstemmed Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients
title_short Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients
title_sort discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan cancer patients
topic Cardiotoxicity
Machine learning models
Multi-omics
Plasma proteomics
Plasma metabolomics
url https://doi.org/10.1186/s40959-025-00309-6
work_keys_str_mv AT jessicaclal discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT michellezfang discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT muznahussain discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT abelabraham discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT reinatonegawakuji discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT yuanhou discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT minakchung discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT patrickcollier discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients
AT feixiongcheng discoveryofplasmaproteinsandmetabolitesassociatedwithleftventricularcardiacdysfunctioninpancancerpatients